Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan

Table 6 Pharmacist and clinician assessment of triptan suitability in subjects recognised by the pharmacist to have contraindications related to cardiovascular disease, or cardiac risk factors

	Suitability assessments by the pharmacists and clinicians
	UK^a (n = 439)	Australia^a (n = 456)	Germany^a (n = 458)
Subjects with at least one contraindication related to cardiovascular disease^b
No. of subjects	37	16	47
Pharmacist-assessed suitability	5.4%	0%	25.5%
Pharmacist-assessed suitability	2/37	0/16	12/47
Clinician-assessed suitability	62.2%	68.8%	72.3%
Clinician-assessed suitability	23/37	11/16	34/47
Subjects with at least three cardiac risk factors^c
No. of subjects	16	11	32
Pharmacist-assessed suitability	0%	0%	9.4%
Pharmacist-assessed suitability	0/16	0/11	3/32
Clinician-assessed suitability	56.3%	63.6%	81.3%
Clinician-assessed suitability	9/16	7/11	26/32

^aSumatriptan 50 mg for the studies in the UK and Australia; naratriptan 2.5 mg in Germany
^bHistory of heart disease, stroke or transient ischaemic attack, peripheral vascular disease/problems with circulation
^cAs listed in the product information for non-prescription triptans: women who are post-menopausal; men aged over 40; high cholesterol; parent, brother or sister developed heart disease before the age of 60; regularly smoke more than 10 cigarettes per day; diabetic; clearly obese

ISSN: 1129-2377